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Abstract
Background: Inhibition of  drug-metabolizing enzymes (DMEs) has been regarded as one of  the most important reason 
for clinical drug-drug interaction. 
Aim: The aim of  the present study is to evaluate the inhibition of  bakuchiol towards UDP-glucuronosyltransferase (UGT) 
2B isoforms.
Methods: In vitro recombinant UGT2B-catalyzed 4-methylumbelliferone glucuronidation was used as the probe reaction. 
Dixon plot and Lineweaver-Burk plot were employed to determine the inhibition kinetic type, and nonlinear regression of  
data was utilized to calculate the inhibition kinetic parameter (Ki). In vitro-in vivo extrapolation (IVIVE) was carried out to 
predict in vivo inhibition magnitude. 
Results: Among the tested UGT2B isoforms, UGT2B7 was inhibited by the strongest intensity. The noncompetitive 
inhibition was demonstrated by the results obtained from Dixon plot and Lineweaver-Burk plot. The Ki value was calculated 
to be 10.7 μM. In combination with the reported concentration after an intravenous administration of  bakuchiol (15 mg/kg) 
in rats, the high risk of  in vivo inhibition of  bakuchiol towards UGT2B7-catalyzed metabolism of  drugs was indicated.
Conclusion: All these results provide an important information for the risk evaluation of  the clinical utilization of  
bakuchiol. 
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Introduction
Drug metabolism plays a key role in the breakdown 
and safe elimination of  the parent compounds. Drug 
metabolism can be categorized into phase I and phase 
II metabolism1. Biotransformation of  parent drug 
during phase I metabolism involves the addition of  
hydroxyl, carboxyl, amino, or thiol groups 2. The drug-
metabolizing enzymes involved in phase I metabolism 
contain cytochrome P450 (CYP) and flavin-containing 
monooxygenases (FMO) 3. Furthermore, phase II 
reactions will increase the hydrophilicity, facilitating the 
excretion of  metabolites into the sinusoidal circulation 
or bile. The metabolic enzymes contain UDP-
glucuronosyltransferases (UGTs), N-acetyltransferase 2 
(NAT2), and glutathione Stransferase (GST) 4.Besides
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the detoxification properties of  drug metabolism, some 
metabolic behaviours of  drugs might result in the toxicity. 
For example, acetaminophen (APAP) can underwent 
CYP3A4, 1A2 and 2E1-mediated bioactivation to 
form reactive metabolite Nacetyl pbenzoquinoneimine 
(NAPQI) which plays a key role in the hepatotoxicity 
of  APAP 5.  
Human UGT superfamily can be categorized into two 
families (UGT1 and UGT2) and three subfamilies 
(UGT1A, UGT2A and UGT2B). Some UGT isoforms 
are highly expressed in the liver, including UGT1A1, 
1A3, 1A4, 1A6, 1A9, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17 
and 2B28. Additionally, some UGT isoforms have been 
detected only in the gastrointestine (GI) tract, including 
UGT1A7, 1A8 and 1A10 6. Many factors can influence 
the activity of  UGTs, including the nuclear receptors 
(e.g., pregnane X receptor, liver X receptor, farnesoid X 
receptor, etc.) and microRNAs 7,8. 
The activity of  UGTs can directly be inhibited by clinical 
drugs, and the severe clinical results might occur. For 
example, sorafenib, the approved drug for the treatment 
of  renal cell and unresectable hepatocellular carcinomas, 
has been reported to induce hyperbilirubinemia through 
the inhibition of  UGT1A1 activity 9. Additionally, 
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unconjugated hyperbilirubinemia induced by indinavir 
might be resulted from the inhibition of  indinavir 
towards UGT1A1 activity 10.
Bakuchiol, a prenylated phenolic monoterpene isolated 
from the seeds of  Psoralea corylifolia L. (Leguminosae), 
has been reported to exert a variety of   pharmacological 
activities, such as anti-microbacterial activity and 
inhibition of  iNOS expression 11,12. Bakuchiol has been 
demonstrated to have anti-cancer activity 13. Bakuchiol 
has been reported to exhibit regulation effects towards 
the enzyme activity. For example, bakuchiol has been 
demonstrated to protect mitochondrial respiratory 
enzyme activities against both NADPH-dependent 
and dihydroxyfumarate-induced peroxidation injury14, 
indicating the good interaction between bakuchiol and 
enzymes. Therefore, the present study aims to evaluate 
bakuchiol’s inhibition towards UGT2B isoforms, trying 
to indicate the potential influence of  bakuchiol towards 
the metabolsim of  xenobiotics and endogenous 
substances mediated by UGT2B isoforms.
Methods
Chemicals and reagents
Bakuchiol was purchased from SichuanWeikeqi Bio-
technology Co. Ltd (Sichuan,
China), and the purity of  bakuchiol was demonstrated 
to be more than 98% by HPLC analysis. 
4-methylumbelliferone (4MU), 4-methylumbelliferone 
β-D-glucuronide, and UDP-glucuronic acid (trisodium 
salt) were purchased from Sigma-Aldrich. Recombinant 
UGT2B7, 2B15 and 2B17 were obtained from BD 
Gentest Corp. (Woburn, MA, USA). Acetonitrile and 
methanol (HPLC-grade) were purchased from Merck. 
High purity water was obtained from Milli-Q water 
purification system (Millipore Corporation, Bedford, 
MA, USA). All other reagents were of  analytical grade. 
Inhibition evaluation of  bakuchiol towards recombinant 
UGT2B activity
The inhibition capability of  bakuchiol towards UGT2B 
activity was evaluated as previously described 15. 4-MU 
was used as probe substrate to determine bakuchiol’s 
inhibition towards UGT2B isoforms, including 
UGT2B7, 2B15 and 2B17. The incubation mixture 
contained recombinant UGT2B isoforms, 5 mM MgCl2, 
5 mM UDPGA, 50 mM Tris-HCl (pH=7.4), 4-MU, and 
bakuchiol. After 5-min pre-incubation, the reaction was 
initiated by the addition of  UDPGA, and the reaction 
time was 120 min. The reaction was terminated by 
adding 100 μL acetonitrile with 7-hydroxycoumarin 
(100 μM) as internal standard. The mixture was 
centrifuged at 20000 × g for 10min and an aliquot of  
supernatant was transferred to an autoinjector vial for 
chromatographic analysis. The concentrations of  4-MU 
and recombinant UGT2B isoforms, and the analytical 
conditions were used as previously described 16,17. In 
brief, the concentration of  recombinant enzymes was 
0.05, 0.75 and 0.5 mg/mL for UGT2B7, 2B15, and 
2B17, and the used concentration of  4-MU was 350 
μM for UGT2B7, 250 μM for UGT2B15 and 2000 μM 
for UGT2B17.
Determination of  IC50 values
The IC50 values were defined as the concentrations of  
bakuchiol exhibiting 50% inhibition. The IC50 values 
were determined through plotting dose response 
curves of  enzyme activity versus the concentrations of  
bakuchiol. 
Determination of  the inhibition kinetic type and 
parameters
The reaction velocity was determined at the different 
concentrations of  4-MU and bakuchiol, Dixon plot and 
Lineweaver-Burk plot were used for the determination 
of  inhibition kinetic type. The inhibition kinetic 
parameters (Ki) were calculated through nonlinear 
regression using the equations for competitive inhibition 
(1), noncompetitive inhibition (2).
V=Vmax*[S]/(Km/(1+([I]/Ki))+[S]) (1)
V=Vmax*[S]/(Km+[S])*(1+([I]/Ki)) (2)
Where the items are defined as followed: V is the 
reaction velocity, [S] and [I] are the concentrations of  
substrate and inhibitor, respectively. Km value is the 
substrate concentration in which the velocity reached to 
half  of  the maximum velocity (Vmax) of  the reaction. 
Ki value is the inhibition constant. 
Prediction of  in vivo risk from in vitro data
The [I]/Ki value has been widely regarded as the 
common method to estimate the in vivo risk due to the 
inhibition of  drug-metabolizing enzymes 18,19. When 
this value is more than 1, the possibility of  drug-drug 
interaction is high.
Results
As shown in Fig. 1, bakuchiol exhibited dose-dependent 
inhibition towards all the tested UGT2B isoforms, 
including UGT2B7, UGT2B15, and UGT2B17. The 
inhibitory potential of  three concentrations of  bakuchiol 
towards these three UGT2B isoforms was evaluated. 
At 1 μM of  bakuchiol, the activity of  UGT2B7, 2B15, 
and 2B17 was inhibited by 3.5%, -3.9%, and 1.9%, 
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respectively. At 10 μM of  bakuchiol, the activity of  
UGT2B7, 2B15, and 2B17 was inhibited by 26.3%, 
-7.8%, and 10.0%. The activity of  UGT2B7, 2B15 and 
2B17 was inhibited by 89.4%, 58.3%, and 6.7% at 100 
μM of  bakuchiol. 
Fig. 1 Initial screening of  bakuchiol’s inhibition towards 
UGT2B isoforms. Three concentrations (1, 10, 100 μM) 
were selected. The experiments were performed in duplicate, and the data were given as mean.
Due to the strongest inhibition of  bakuchiol towards 
UGT2B7, more concentrations of  bakuchiol were 
selected for the determination of  IC50 value, and 
the results were given in Fig. 2. Bakuchiol exhibited 
concentration-dependent inhibition towards UGT2B7, 
with the activity of  UT2B7 inhibited by 5.3%, 14.5%, 
20.5%, 36.9%, 49.1%, and 74.1%, for 1, 5, 10, 20, 40, 
and 80 μM, respectively. The IC50 value was calculated 
to be 40.9±0.5 μM. 
Fig. 2 IC50 curve of  bakuchiol’s inhibition towards UGT2B7. The experiments were performed in duplicate, and 
the data were given as mean±S.D..
566 African Health Sciences Vol 14 Issue 3, September 2014
The inhibition type can be categorized into competitive 
and noncompetitive inhibition, and a combination of  
Dixon plot and Lineweaver-Burk plot can be the most 
common method to determine the inhibition type. 
The results (Fig. 3A & 3B) indicated noncompetitive 
inhibition of  bakuchiol towards UGT2B7. Nonlinear 
regression of  data using noncompetitive fitting equation 
was furtherly performed to calculate the inhibition kinetic 
parameter (Ki) to be 10.7 μM. The in vivo maximum 
concentration of  bakuchiol was reported to be 4090.6 
ng/ml (16μM) after an intravenous administration of  
bakuchiol (15 mg/kg) in rats 20. Arbitrarily supposed 
that the concentration of  bakuchiol in human was equal 
to that in rats, the [I]/Ki was calculated to be 1.5. 
Fig. 3 Determination of  inhibition kinetic type. (A) Dixon plot of  bakuchiol’s inhibition towards UGT2B7. (B) 
Lineweaver-Burk plot of  bakuchiol’s inhibition towards UGT2B7. The data point represents the mean value of  
two experiments.
Discussion
UGT2B7, arguably regarded as the most important 
UGT isoforms, can catalyze the glucuronidation many 
drugs, including nonsteroidal anti-inflammatory drugs 
(NSAIDs) and opioids 21. Some previous reports 
have indicated that the inhibition of  UGT2B7 activity 
can elevate the exposure of  some drugs mainly 
undergoing UGT2B7-metabolized elimination. For 
example, efavirenz (EFV), the non-nucleoside reverse 
transcriptase inhibitor (NNRTI) agent to treat HIV 
infection, can induce 225% elevation of  zidovudine 
(AZT) exposure in plasma through inhibition of  
UGT2B7-catalyzed AZT glucuronidation 22.   
UGT2B7 was highly expressed in all tissues, including 
liver, small intestine, colon, kidney, and bladder 23. 
Therefore, bakuchiol can affect the activity of  UGT2B7 
in all these tissues. It should be noted that the maximum 
plasma concentration of  bakuchiol was used for in vitro-
in vivo extrapolation (IVIVE), which was suitable for 
IVIVE for liver UGT2B7. However, the concentration 
of  bakuchiol in other tissues was significantly different 
with that in the liver. For example, the concentration 
of  bakuchiol in the intestine was higher than that in 
the liver given that bakuchiol needed to undergo the 
absorption and first-pass metabolism. Therefore, the 
in vivo inhibition magnitude might be higher for the 
inhibition of  bakuchiol towards intestinal UGT2B7. 
Another important reason to influence the in vitro-in 
vivo extrapolation (IVIVE) is the elimination ratio due 
to UGT2B7-catalyzed metabolic elimination. In the 
present study, the ratio was arbitrarily to be 1, which 
made the prediction value maximum. Therefore, when 
the metabolic contribution of  UGT2B7 towards the 
metabolism of  drugs was less than 1, the in vivo inhibition 
magnitude will be lower. Additionally, many factors 
might influence the quantities of  herbal components, 
including processing of  herbs and environmental factors 
(soil, altitude, seasonal variation in temperature, length 
of  daylight, rainfall pattern, shade and dew), which also 
affect the IVIVE process. 
In conclusion, the inhibition capability of  bakuchiol 
towards important UGT2B isoforms was evaluated 
in the present study. UGT2B7 was strongly inhibited 
among the tested UGT2B isoforms, and high possibility 
of  in vivo inhibition was predicted through in vitro-in 
vivo extrapolation (IVIVE). Co-administration use of  
bakuchiol and drugs metabolized by UGT2B will need 
further evaluation 
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